<SEC-DOCUMENT>0000950170-25-071385.txt : 20250514
<SEC-HEADER>0000950170-25-071385.hdr.sgml : 20250514
<ACCEPTANCE-DATETIME>20250514161011
ACCESSION NUMBER:		0000950170-25-071385
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250514
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250514
DATE AS OF CHANGE:		20250514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acrivon Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001781174
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				825125532
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41551
		FILM NUMBER:		25945536

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL WAY, SUITE 100
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-207-8979

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL WAY, SUITE 100
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>acrv-20250514.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-13T11:30:14.3825+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:acrv="http://acrivon.com/20250514" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_33d4e64f-3f52-4ba0-bef6-6779b565e7ba" name="dei:AmendmentFlag" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8">false</ix:nonNumeric><ix:nonNumeric id="F_23a37b71-388a-4bbc-9ddf-f9fbb14f948e" name="dei:EntityCentralIndexKey" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8">0001781174</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="acrv-20250514.xsd"/></ix:references><ix:resources><xbrli:context id="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781174</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-14</xbrli:startDate><xbrli:endDate>2025-05-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8fd061a5-7eb9-44cc-83aa-3e3e3933d768" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_a28e4c0b-3c40-4fdc-8176-cdc2220969dd" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">May 14, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25f5da7f-4a45-4653-bd58-bc95a3b90a34" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acrivon Therapeutics, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1abd551b-5446-4d76-81d8-1adaf1e1af9a" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_53aebc5f-74ec-4d8c-b60b-ce4f208eaaa2" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-41551</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_25c452f7-32d4-416b-8fac-c81296bb7955" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">82-5125532</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_22ef86de-a4cd-44f3-a98e-377f91b2ec3f" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">480 Arsenal Way</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7585b826-1ebe-4bee-8ff7-481e2cb2df08" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 100</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e892e497-5b05-402d-92b9-9a4e4dd7433c" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Watertown</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_16c4511b-e945-4a2f-9e24-efde486800c1" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_001dcf43-9ffa-410e-b828-4388e7d8a959" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02472</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_dac99808-dea7-4937-8bb0-849ce2c10bd9" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(617)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_26fac416-9d34-42e7-83b3-97977c9cd7a9" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">207-8979</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb36f590-d221-4caf-91cf-cfc71492eeb0" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58e8ed3b-a4e9-4311-968d-059d5e779b4a" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_faf7ccac-f898-4e8a-a0c9-87f5a1175adb" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9182866-2e72-4c73-97b4-8490b41214ba" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_151bd1c2-dd8f-4e64-b98e-85ce23891f86" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_817ba231-3023-4eb4-96aa-6d85da26929b" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ACRV</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ccf23ca2-0ee6-431b-a483-621c2d860d5f" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_c02ad7c9-cafc-478a-8f11-b180d94efa77" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_83b582c6-feb3-46da-8fa1-a295d4688f41" contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 14, 2025, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended March 31, 2025, and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:7.08%;box-sizing:content-box;"/>
     <td style="width:2.02%;box-sizing:content-box;"/>
     <td style="width:90.9%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acrv-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release, dated May 14, 2025</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acrivon Therapeutics, Inc.</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Peter Blume-Jensen</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Peter Blume-Jensen, M.D., Ph.D.<br/>Title: President and Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>acrv-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><img src="img28311487_0.jpg" alt="img28311487_0.jpg" style="width:336px;height:104px;"></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate R&amp;D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) &gt;5.6 months (not yet reached) observed in OncoSignature-positive (BM+) patients, a majority of whom were refractory to last prior therapy, and cORR of 50% and mDOR &gt;10 months (not yet reached) for BM+ patients who had relapsed on last prior therapy</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Three dose escalation cohorts completed in ACR-2316 Phase 1 trial with tumor shrinkage observed already at dose level (DL)3, below projected recommended Phase 2 dose</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">AACR presentation of ACR-2316 revealing mechanisms underlying its superior preclinical activity with potent mitotic tumor cell death using AP3 Generative Phosphoproteomics</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Mansoor Raza Mirza, M.D. appointed chief medical officer; accomplished clinician with stellar track record of successfully leading registrational trials through regulatory approvals, and establishing new standards of care in gynecological oncology</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities of $164.8 million as of March 31, 2025, expected to fund operations into the second quarter of 2027</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">WATERTOWN, Massachusetts, May 14, 2025</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> &#x2013; Acrivon Therapeutics, Inc. (&#x201c;Acrivon&#x201d; or &#x201c;Acrivon Therapeutics&#x201d;) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision oncology medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased and actionable manner, today reported financial results for the first quarter ended March 31, 2025 and reviewed recent business highlights.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;We made substantial progress in the first quarter in the advancement of our clinical pipeline and the expansion of our Generative Phosphoproteomics AP3 capabilities, as well as strengthening the executive team,&#x201d; said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. &#x201c;At our corporate R&amp;D event, we reported positive updated interim data from our ongoing ACR-368 Phase 2b study in endometrial cancer patients with large tumors and aggressive histopathologies &#x2013; all of whom had progressed after prior platinum-based chemotherapy and anti-PD-1. With a significant unmet need for second-line treatment options and the potential for label expansion through a confirmatory trial in the front-line setting with ACR-368 used as switch maintenance, we remain very excited by the opportunities for this program. For our second clinical-stage asset, ACR-2316, we have</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">observed tumor shrinkage (~25%) in a patient with significant metastatic solid tumor burden after only six weeks of treatment at dose level 3 - well before reaching our projected RP2D, supporting its potential for monotherapy activity. Finally, we are thrilled and feel privileged that Dr. Mansoor Raza Mirza, a globally recognized oncologist, is now leading the development of our pipeline as CMO. Mansoor has made significant contributions in clinical oncology as a lead investigator for multiple approved drugs and senior author of national cancer guidelines.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Recent Highlights</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Presented interim data (February 25, 2025) from the ongoing Phase 2b registrational-intent trial of ACR-368 in patients with heavily pretreated endometrial cancer who had all progressed on prior anti-PD-1 and chemotherapy</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Among the 20 OncoSignature-positive (BM+) patients, the confirmed overall response rate (cORR) was 35%, more than double that in the prior line of therapy, and the disease control rate (DCR) was 80% </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In the BM+ patients that had relapsed after the prior line of therapy, the cORR was 50%, mDOR was not yet reached (&gt;10 months), and DCR was 100% </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In the BM+ patients with tumors refractory to last prior line of therapy, significant clinical activity was observed with a cORR of 33% and DCR of 75% </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Provided an overview of the expanded capabilities of the company&#x2019;s Generative Phosphoproteomics AP3 platform highlighting the growing suite of powerful, internally-developed tools, including the AP3 Data Portal, designed to convert multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor, and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Advanced to DL4 in the Phase 1 monotherapy clinical trial of ACR-2316, with encouraging observations at DLs 1-3:</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">DL 1, 2, and 3 cleared without safety concerns or dose-limiting toxicities (DLTs) by the safety review committee, and DL4 is now enrolling</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Drug target engagement observed at DL1 and 2 using the company&#x2019;s clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Notably, initial clinical activity of ~25% RECIST tumor shrinkage and a reduction of metastatic lesions throughout the chest, abdomen and pelvis was observed after six weeks of treatment in a patient at DL3 (below projected RP2D) who had received three prior lines of therapy including chemotherapy and anti-PD1 </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Presented at the AACR Annual Meeting Generative Phosphoproteomic AP3 analyses uncovering key molecular mechanisms by which ACR-2316 induces strong mitotic and replicative tumor cell death believed to be critical for its potent single-agent activity</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Appointed Mansoor Raza Mirza, M.D., as chief medical officer, bringing decades of experience as a distinguished and highly accomplished oncology key opinion leader with a stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Promoted Adam D. Levy, Ph.D., M.B.A., to chief financial officer, having served as the company&#x2019;s head of investor relations and with prior finance and strategy leadership roles </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">at Zentalis Pharmaceuticals, Turning Point Therapeutics, Novartis, Gilead, and McKinsey &amp; Company</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Anticipated Upcoming Milestones</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Provide update on registrational-intent trial and confirmatory trial design for ACR-368</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Report initial clinical data from the Phase 1 clinical study of ACR-2316 in the second half of 2025</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Advance a new potential first-in-class cell cycle drug discovery program for an undisclosed target towards development candidate nomination in 2025</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">First Quarter 2025 Financial Results</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Net loss for the quarter ended March 31, 2025 was $19.7 million compared to a net loss of $16.5 million for the same period in 2024.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Research and development expenses were $15.4 million for the quarter ended March 31, 2025 compared to $11.5 million for the same period in 2024. The difference was primarily due to the continued execution of the clinical trials for ACR-368 and ACR-2316, as well as preclinical drug discovery advancement and increased personnel to support these research and development activities.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">General and administrative expenses were $6.2 million for the quarter ended March 31, 2025, which is materially consistent with the same period in 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the company had cash, cash equivalents and investments of $164.8 million, which is expected to fund operating expenses and capital expenditure requirements into the second quarter of 2027.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About Acrivon Therapeutics </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Acrivon is a clinical stage biopharmaceutical company discovering and developing precision oncology medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company&#x2019;s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing with enrollment in the first three dose-escalation cohorts completed. Drug target engagement was observed at DL1 and 2 using the company&#x2019;s clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses, and initial clinical activity with tumor shrinkage observed at DL3. The company also has a preclinical cell cycle program with an undisclosed target.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Forward-Looking Statements <br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This press release includes certain disclosures that contain &#x201c;forward-looking statements&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; or &#x201c;would&#x201d; or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon&#x2019;s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled &#x201c;Risk Factors&#x201d; in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Investor and Media Contacts: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br>Adam D. Levy, Ph.D., M.B.A.<br>alevy@acrivon.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Alexandra Santos <br>asantos@wheelhouselsa.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:48.25%;box-sizing:content-box;"></td>
     <td style="width:2.2%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:11.102%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:2.2%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:11.102%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:21.144%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Acrivon Therapeutics, Inc.<br>Condensed Consolidated Statements of Operations and Comprehensive Loss<br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(unaudited, in thousands, except share and per share data)</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,414</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,473</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,248</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,195</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,662</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,668</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21,662</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(17,668</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense), net:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</font></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,996</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,446</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</font></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(264</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</font></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,982</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,182</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19,680</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16,486</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share - basic and diluted</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.51</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.73</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common stock outstanding - basic and diluted</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,350,444</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,590,804</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19,680</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16,486</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income (loss):</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized (loss) gain on available-for-sale investments, net of tax</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(164</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19,844</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16,473</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:61%;box-sizing:content-box;"></td>
     <td style="width:3.18%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:14.6%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:2.62%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:14.6%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Acrivon Therapeutics, Inc.<br>Condensed Consolidated Balance Sheets<br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(unaudited, in thousands)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,154</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,818</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,676</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144,751</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,519</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,019</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,349</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196,588</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders' Equity</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,959</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,802</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders' Equity</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">160,390</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,786</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Liabilities and Stockholders' Equity</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,349</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196,588</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img28311487_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img28311487_0.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "P CT# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0HHHK,T"BBB@ HKG8/&'A*Y\2WG@RV\4>';CQAI]BNIW_A2#6],E\2V.FO\
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M^FJZ5JFHZ9J<4AECU+3[VYL[^.5FWM(EY;2QW"2%P&+K(&+?,3GFOOWX ?\
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MWM112$@ DD  $DDX  Y))/  '4U\6?3"T5_G^?\ !3K_ (*A_M'_ !%_;/\
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MW,JD</44\%B)M1A"NXNE4DVDH0K1LN=O1*I"GS.RBY2:1^]5%%%?"'U845_
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M(-4\6Z7X3\-:;XJUR(0:UXFL-"TNS\0:O # 1#JFLV]K'J.H1 VML1'=W,R
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M>*O'_CO5H]*T/2H9$@BWE'N+S4-1O9BMOIVDZ790W&HZKJ-RZP65C;3SR$[
MK?7'_!5OXPW_ ,;O^"@G[3GBNZOGO+'1/B/JOP[T!"ZO'9:%\.2O@ZUM(-I9
M1&;C2;N[D /S75W<.0I<JO[Y?\&S'[-VAP^$OC?^U9K.FQ7'B6^U^'X.>"+V
MXAC>32]#TZPTSQ)XPN;"4Y:)]9O]0T.PN&7:_E:*\>?+G</]1@_J_!'!<<;"
MC">-JT*%>HI*SKX_&*/LH5&K2=+#*:BX)K]W2FXVG.4GX.(]MQ1Q*\-*I*.&
MA5J4H6>E+"8=RYY03NE4K<KE=I_O*D4TXQ27V;^QC_P0"_9(^!/AK1]:_:&T
M2U_:4^+SQ6]WJT_B274K?X7:!?-'F?2_#?@BWN+.UU^PA9C#)J/CJ/6Y-1>)
M;VUTG0!*;"/])[W_ ()X?L$7]C+IT_[%G[*T=O-$87DLO@'\+]-O@C*4+1:I
MIWABUU."7!)$\-W'.K8=9 X##[%HK\4QG$&=8ZO+$XG,\;.I*3DE#$5:5.GK
M?EI4J<H4Z45TC3C%7U=W=GZ?ALHRS"4HT:&!PT8)6;E1A4G/I>I4FI3J2?5S
MDWTV21_,S^WC_P &[WP7\<>&-<\>?L4"Y^%'Q*TZTN-0B^%&KZYJ.M?#;QK)
M"LD\FG:3J/B"ZU#7?!6NWK$I8S-JU_X4\Q;>P;2-$MY)=4M_XUO$7A[QA\,_
M&6K>&?$FFZUX,\=>!]?N=,U;3+U+C2M>\-^(]"O6BGAD ,=S9:AIU];YCEB=
M7CEC2:"0C8Y_UCZ_BO\ ^#E+]F+1/ /QN^$_[2_A?3;?3XOC7HVJ^%?'JVT2
M0QWGC;P-%I[:9K<J(H$E[J_AG4(;*\E.&?\ X1Z"5S)+/(]?I?A_Q?CL5C8Y
M'FE>>+C7IU'@L17DYUXU*4'4E0J5)7E5A.E&<H2J.4XRCR<SC)*/Q'%W#N%P
M^&>:8"E'#^RG!8JC22C2<*DU"%6G!6C3E&I*,91@E&49<UHN+<OVL_X(H?\
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M[*^M&#4I;@:1X3\+PW8EB_X2#Q%]AO@FI7-K=:?H=C:76HW=O>3K8Z;J$/\
MP6?_ .4G/[67_8W>$?\ U5_@:OVS_P"#7;_D _M?_P#87^$7_I%X[K];S#,<
M5E/ .&QV#DH8FEDV3PI5'%2]FZ\,'0E4BGHYPA4E*',G%346XR2<7^>X/!T,
M?Q95PN)BYT*F99A*I!/EYU2EB*R@VM>64H*,[--Q;2:=FOZ-OV=_V1/V;OV4
M_"]GX4^ OPA\&^ +:WM(+6]UO3])MKCQAX@:!2!=^*/&5ZEQXF\17CLSOYNJ
MZG<K"',-K';VRQPI'^TK^R+^SU^UMX&U3P)\=?AEX9\96=[97-MINOW&F6L/
MC'PK=S1LD6K>$O%<,2:WH&HVSE95DL;R."Z53:ZA!>6,L]K+])T5_/?U[&_6
MOKOUO$_7.?VGUIUJCQ'.G?F]LY<][]>8_7_JF%]A]5^KT/JSCR>P]E#V/+:W
M+[/EY;?(_P LK]JWX ZU^RW^T9\7_@!KURU_>?#'QIJ6@6VJ-&8FUC1&\O4/
M#FM&/8BQMJ_A^]TS471%\N.2Y:.-F10Q_L%_X-M?COK7Q!_9-^(OP<U_4);]
M_@9\14C\,_:)WFFM/!_CVQEUNVTY/,9G2UL_$-EXC>VCR(XHKM8(0L<01/PG
M_P"#@?2;+2_^"E/Q$FLXS&^L?#WX5ZM?$[<27LGA6"Q:085< V]C;K\VYLJ2
M6P0!]]_\&O&JS)\0?VN]#+.;>X\&_"C557*[$FM-;\9V;L1MWEY([V, []JB
M(_*2V1^Z\43_ +6\/J>85XIXCZIE6/YK)<M>I/#TZTHVTCS1K54DOLRL?E61
M1>7<72P=)M4EB,=A&KOWJ48UI4U+O:5.FW?JKG]AM%%%?@!^NA7XL_\ !63_
M (*YVW_!.&_^%O@CPK\+[+XJ_$KXD:?JGBFYL=;\07/AW0/#/@S3+O\ LFWO
MKF:QL+^^U'4]=UA;RUTZUA6WM[:WT?4KB\N-[65O<?M-7XE?\%/OV6?^"?W[
M=7Q'^%WP9^-O[4?A+X*?M,^#%:U\$Z3IWCSP-:>--6T3QQ+:7,7A;5O!?B:Y
M5]5.L3V%OJ'A:V@DT_6UN+AI[ 7MEJLEK=^[PW#+99M0>;X;$8K+H0K3Q-/#
MPK5'&,:4N2K4CA[5G1A4<'4<&K*U^:-XR\?/IXZ&6UO[-KT</C9RI0H3K3I4
MU)NI'GITY5W[)59P4E#G3OJE:5I1]2_X)U_&W]E7_@HOX L?VV+7]FOX5^"?
MC[X/\2ZQX#\;Z]J/A/PCKGC;POXJTK3_  _K;WNE?$63P]INOZCI5[HNH:+J
M.C:Q=):7VEK-J>C1R!K;49KOTKQ3_P %"?V/O%NL:K\(_$UQKNO>%/$1NO"^
MM^(KOPV&\ 7%M>,]C<?:;Q]1AUY=/+$LFK6NAF&!0FH074<<:W*=U^RY^PA\
M)OV.?V7-=_9E^"MSK2V7B.R\7WGB'QMXFN+6Z\3>)O&OB_1$T2[\5:S)IEEI
M]C$UI96FDZ9IMCI]A!#8Z-H^GVS?:[U+K4+S\,T_89_:FD\=MX!7X1^(_MJW
MLMK_ ,)(\*Q>!#;PX=]27QI,8] :R:W(N(HA>?VG/S9PZ?)J8-B/P7QYXUXO
MR#,LHP_ /#]7.\ES/$XW#5(8S+<;G*]A&>'AA<H=&C4;P]'&0K8FT:W-4K4U
MR4Y1G2KN7]&?1XX!X$XGP&?8KQ#XHAP]G&48; XK#2PF:Y?D4_;2CB:F+SE5
M\12MB*V J4,*FZ'+3H5)<]53A5H*'[@?"_\ X)Y_LW_#+Q_IGQ-\/6WBK6[_
M $JXCU7PUIOB#Q#;:KX;T6_5A-8ZKIT%KI=E>WT]F"'L'UC5-6MXG,=VL37D
M-O<Q?==<EX \-2^#/ G@KP?/>MJ4WA3PEX;\-3:@[,SW\NA:/9:7)>NSA79K
MI[4SLS@,3(2P!)%=;7WW#G#^3</8!4,FR3 Y%#%N.,Q>#P-*G3BL75IP515)
MTTO:RI65*,OAC""C34862_+^*.)<]XFS)XG/<_S'B*I@XRP."QV8UZM6;P5*
MK-TO9PJRDZ,:O,ZTX_%*I4E*I*=1RDRBBBO?/FSB_B3X^\._"GX=^/OBCXOF
MGMO"?PV\%^*?'WBBXM81<74'AWP=H=_XBUN:VMVDB6>>+3=.N7AA:6(2R*J&
M1 VX?R^_ #_@NW\._P!N_P#:*\(?LG_M(_LA?#A?@7\<_%=IX%\,Q^)-6A^)
M4^F^+=9E%CX$/B?1O$'A>VT'5SJVNRVVBK>:59:->Z!?:Q:ZE:7%RNGRK=_T
MN_'3Q!\&?#WPF\=O^T%XE\&^%O@]K?AK6?"WCN_\>^(K/PMX:N_#WB73+O1]
M5T:]U:\OM.$;ZQIUU=6$,%I=QZC<O-Y5AFZ,8K\//V"/^"+_ .P5X'^,GAK]
ML+X)?M :K^TCX3\)>)M5UKX5Z=IWB3P7XB\$>%_$D$WG:*VL>(/":S7/B#Q#
MX'MKRV>"UO)=&EAUF.RU75-+62*.RKZ_A^604,MS;$9OAL;+%J"AE6*H1Q,:
M=+$JG4E%4Z]&4*5/$*K[*HW7;BH17+O.,OF,Z6<ULPRVAEE?"K#<W/F.'JRP
M[G4H>T@I.K2JQE5G0E3]I"U%7<G+FL_9RC]L?M_N_P"SI^RIX=\"_L_^'-)^
M$O@C4O&&G^$M1T[X::)8^#M)T/PS<:7K>J3:3IMIX;M=/MM$M]=U&PM;?4)[
M-;;[?:_:]*NC/!JUS%+^=7_!-OXA_$+0OVE/"7@OP]JFIS>$_&S>(!XR\/&:
M>;2;F"P\,ZKJ,6N3VS/]GMM2T^ZL;3RM3"K<R1L=-,DD=YY+_J?\5_VZ/V1)
MO%6M_ KXAKJ7BK1Y]1N?"WB[4Y/"\6K> M,O;:66"\BU&YEO8]7G&FW\'D'4
M] T74EM;U8[NRNO+@:\A^D/@E\ ?@)\(;2YU_P""O@[1-&@\8V-E>OXAL=5U
M;Q)/JVD7,4-[8BPUS7=5UF[CT2Z0V][%9Z==PZ9<N(+OR))%CE'\BYKPO5X]
M\6<MXPX=X^RS%8/AC$X&GG&7X;'UZ^9X">#KSJ8G!X>E0Y\/4PV<2C5H8RM5
MKT:?-4Q490QCIRHG]EY-QA1\./!?-N!^*?#;-L)F'%^%S&KD>:8O+L/ALJS*
M&.P].EA<?BJV(Y,53Q>1QE1Q&"H4,/7J<M/"24\"JRKGO5%%<MHWCGP3XCU*
M^T?P]XP\+:]J^F)YFI:5HWB#2=4U+3XPXB+WUC8W<]U:)YC+'NN(HUWL$SN(
M%?T/.M1ISITZE6G3G6DXT83J1C.K**YI1IQDTZDE'5J*;2U:L?S!3H5ZL*M2
ME1JU*="*G7J4Z<YPHPD^6,JLHIQIQE+W5*;2;T3N?.WQ#_;L_8]^$_Q>TCX"
M_$?]H?X:>$/B[K4^D6MKX*U?7!%?VMWKY7^Q+/6[R.&72?#=YJJR02V%KXBU
M#2[BY@O+"XBC:#4+*2X^LJ_A(_;E_P""+G[??C[]OGXMWO@#X?7GQ(\!?'3X
MO^)O'WAOXQW/B/1H/"N@:!XZU^[\07$'CJ\O]0CU70)? =M?3:3>60TJ:YU6
MVTB%/!VGZR][IEA-_<;X$\/WOA+P1X-\*ZCJ\WB#4/#/A7P]X?O]>N%E2XUN
M]T;2+/3;K5YTGN+N=9M2GMI+R59KNZE5YF$EQ.X,K?5Y_E&49;A,GKY;FT<Q
MK8[#2JXRDI4I/#S4:,D^6G[U!2E.I3]C7;JJ5*6KM)1^9R;,\SQ^*S.CCLM>
M"I82O[/#5'&I'VL>::<7*I[M62C&%3VM%*FXSCI9Q<NJHHHKY@^A"OYO/VQ_
MV0?CQ:_M!>/?$7A;X>^,OB!X9^(GBG4?%>B:WX5T?5/$T=L?$5Y)?7.E:P;"
M"ZET1M(O9Y[*(ZB+>Q&G16DUO.+<E(?Z0ZY/Q[XJC\"^!?&GC>6PGU6+P;X3
M\1^*I-,MI4AN=2C\/:/>:N]A;S2JT<4]XMF;>*6162.217=2H(/YUXE\ Y-Q
M]D=+"9SC<7EU+*L1+-*>-P:A.=*-*A5AB(U*-2%2-6E.A*3:C%58U(4Y0DTI
MTZGZEX3>).?>&O$5;'9%@,%FM;.,+')ZN7XYU*=.M*MB:-3#2IUJ52E*C6AB
M(1BI2DZ4J=2I&I%-PJ4_G#]AWX/>,?@A^SUX:\'>/"+?Q-=:GK7B2^T=;F&\
M3PZFMW*2V^B"XM\P//!!$EWJ"P23P1:I>7T,%S<0QI,_XO\ QV_X(:_\$_/A
M)\;/%'[87QQ^/.H?#7]G2/QG_P )QK_PC\4?V!IGA >(=8U,ZB/"T/C2]N)M
M4O?"NKZY+)%9^"+/P]=^(+S3I3H-CK4@"S#-T[_@I%^U+:>/?^$SO/%VG:CI
M<MZ);GP"^AZ;!X/.FF:.1])LXT@?6;)%BC$,&IC5YM94%GN+^[:2<3?3'_!;
MW]D#X]_MU_LE_"FY_9WTZXU_Q!X'\86?Q)U/X57&IVND:AXJT;7/"5W8I+82
MZAJ-EHESXF\*M?\ ^C:9>LDMY9ZEK*Z7>QWL<>G:MV_1\\1N&\]IQX7X2S+.
MLARW(\-EV2XS$YK3PL*];+?9UJ6#QBK1J8BA"K6EA:L?:M8>IA*E1R5.G1E8
MCZ1OACQ?PSC'Q9QK@LBSO,N*,7F>=X:EDE7%SPV'S-UL/7Q^"=&I2PV(=/#K
M%TI1IQ>)IXNE32=:K6BV?K3\"/VC_@7^TYX0D\>? /XH>%/BEX5M[TZ;>ZGX
M8OS/)I>I"&.X_L[6=-N8K75=%OS;RQSK9ZK8V=RT+K*L10[J]LK^=/\ X-_O
MV!/VE?V._"_Q[\<?M$Z#<?#N?XP2> -/\+?#2[UBQU#5[:V\$R>,9+[Q/XCL
MM(OK_3=,N+Y_$=O8Z+:2W!U=+2WU&:^M[2"YLA/_ $65^GY[@L%EV:XO!Y?C
M%C\'1G!4L4I0FI\U*$YQ<Z7[N;I5)2I2G"T9.#:2V7X[D^+Q>.RW#8K'89X/
M$U8S=2@XSAR\M2<(24*G[R"J0C&I&,VVE)>])6;***Q/$WB/1O!_AS7_ !9X
MBOH-,T#PQHVI^(-;U*Y=8[>PTG1[*?4-1O)G8A5BMK2WFF<D@!4->2DY-1BF
MY2:225VVW9)+JV]$CTFTDVVDDFVV[)):MMO1)+5M['\JG_!R[^U<+32/A)^Q
MUX9U/$^K2I\7_BA;V\R[AIUE)=Z5X T:]C&3LNM076]>DB?:0^F:1.,JPS_,
MM^RI^S!\3OVQ/CAX0^ /PC318_&/C#^TYHM3\3W6HV'AC0M-T;3;G5-2UGQ%
M?Z3I.NZC9Z9:P6WE-+9Z1J%Q)=7%K;16TDDZBM?]L_\ :/US]K3]IWXP?'K6
MYKEHO'/BZ_F\-V5P\A.C>"]-8:7X.T:.-_\ 4C3_  ]9Z?%-&JJK7AN9V7S)
MG)_IQ_X-I?V41HO@KXK?M@^)=- U#QG=R?"CX9SW$*EX_#6A7,&H>.-7LG9=
MPCU7Q!'IFB&16^_X;O8N SAOZ)YH\#\%1:4%C:=&-E))JIFF,:;35U[2-!MN
MUU>AA[=#\<M+BGB9_%]6J57>S:<,#AE;1Z\LJD4O2K6/A/\ XAFOV[_^BL_L
MD?\ A>?&/_YPM'_$,U^W?_T5G]DC_P +SXQ__.%K^Y.BOS3_ (B5Q/\ \_<%
M_P"$</\ Y+^KORM]O_J5D?\ S[Q/_A1+_(_AL_XAFOV[_P#HK/[)'_A>?&/_
M .<+39/^#9S]O!$=U^*W[)4K*C,(X_'GQ@#R%02$0R? B.,.Y&U2\B)DC<ZK
MEA_<K11_Q$KB?_G[@O\ PCA_\E_5WY6/]2LC_P"?>)_\*)?Y'^3=XV\'>(OA
MYXQ\4^ O%VFSZ/XI\&>(=8\+^(M+N4>.>PUG0K^?3=1M761$?]S=VTJ*Q1=Z
MA7 VL*_O,_X('_M<']HO]C#3?AKXDU-[WXB_LW7MM\.M5-U*)+R_\#SPRW?P
M[U8EI9)Y8X-)BN?##S2X=I_#CR-Q,F?PJ_X.)_V1O^%/?M0Z'^T;X8TL6W@C
M]HS37DU^2W1A;67Q5\+6]M9ZZ)?FV0OXDT(Z1K4:(J_:+^WUVY8ER]?)G_!%
MK]K<_LH_MO\ @-M<U-+#X;?&CROA%\0#<S&*QLT\07L!\)^()\XC5M#\4IIZ
MR7$K*EOI6HZNQ/S5^CY]0I<8\&4\?AHIXF%".84(1UE#$X>,H8S"JVK;2KTH
MK[4XTY6>A\7E56IPWQ)+"UY-475>#K2>BE0K.,L/7>R25Z55NVD'-+=G^B;7
M^=Q_P7.T^ZL/^"FW[0ANHC&+Z/X=ZA:DYQ+:S_#CPM''*I(&07AD7C(#(PSD
M$#_1'!!&0<@\@CH1ZU_%%_P<M? '4_"W[1_PH_:)LK*9O#7Q6\ 1^"=6ODC'
MV:W\9?#^ZN'BAN),DBXU/PSK%@ULI $D>C717F%R?SSPRQ-.AQ(Z4VD\7@,3
M0IW=KU(SHXCE7FX4)M==+'V''%"=7)E4BFUA\71JU+=(2C4HW?DIU8+YGOO_
M  :[Z[IHF_:^\,F11K#1_"/75B( =]-1O'&GR2(2,NL=T\:R!21&98BX'FH6
M_K@K_.'_ ."1O[;&G_L/?M>^&O''C&XG@^$WC_39_AM\4Y(EEE_LG0-9O+.Z
MTWQ9]FA#27)\+:W9V5_=1HLDS:,^KI;1374D$;?Z,FAZYHWB;1M*\1>'=5T_
M7-!UW3[/5M&UG2KN"_TS5=+U"".ZL=0T^]MGDM[NSN[:6.>WN(9'BEB=71BI
M!J?$G+J^%XAJXV4)?5LQI4*E&K9\CJ4*%/#U:7-MSP=.,W'?DJ0?6X^"L92K
MY/#"J4?;8.K5A4IW][DJU)5H5+;\LG4E"_\ -"2TT-2BBBOSX^P"OC__ (*"
M?\F-_M;?]F]_%;_U#M5K[ KX_P#^"@G_ "8W^UM_V;W\5O\ U#M5KNRO_D99
M=_V'83_U(IG+CO\ <L9_V"XC_P!,S/\ ,'K_ %&/V)/^3.?V6?\ LWWX1?\
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M==0L?CW\7H;HR$EWD'C_ %]O.)8ECYZLLP+'<0X+8;(K^T'_ (-R-:TS4/\
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MXUL6 86@N(I$M%;YEM5B5B6!-?CN/^"NOB\>.3*WPI\-'X:_;TC%BFHZH?'
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M?Z7=1:O;V4*".&TM/$UIXML=,LXH[+2;/3[9$C7],)?^#I34&LV2#]A^SCU
MQ$)=2_M'336:S8.)&L4^!<$[Q X)A&HHY ($RDY&M\;?^#8.TFOM0U']G/\
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MM/S_ .Q?MOF_V'I_E?:?LWER>3Y\OVU_P2[_ ."7W_#MFP^,%C_PO'_A<_\
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M2G+EFHSCS0DGRRC&2O:23N@HK\S? W_!17_A,_\ @I-\4?\ @GI_PI[^S?\
MA6O@,>-O^%O?\+!^V?VUGP[X%U_^S/\ A /^$(M?[._Y'7[)]M_X36__ .09
MY_V3_3/)M/TRJL1@\3A:6 K5Z?)2S/ 8?-,#+GIR]O@<4YJA7Y82E*G[1TY_
MNJRIUH\OOTXW5U3KTJU3$TJ<^:>#Q$L)B8\LE[/$0ITZLJ=Y12G:G6IRYZ;E
M!\UE)R4DBBBBN8V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHKYM^(_P"U_P#LU_"+XS?#+]GOXD?%OP[X
M4^,?QB\G_A77@G4(-8DO->-Y?3:7IJS:E9:9=:'H+ZUJMO/I/A]/$>J:0WB'
M58I-,T07]\IMQI1HUL15A0P]*I7KU.?V=&C3E5JU/9TYU9\E."E.7)2IU*L^
M5/EIPG-VC&345*D*5.=:K.%*E22E4JU)*%.G&4XTXRG.348*52<()R:3G.,5
M[TDG])4445F6%%%% !1110 4444 %%%% !7SQ^UQXF^)W@S]EO\ :'\7?!:T
MDO?BSX9^#/Q&U[X>6UOI[:M=R>+-*\*ZI>Z.=/TM,MJ6IQW4*2Z9I^R9;S4$
MMK9[>Y21K>3Z'HK6C45*M1JRIQJQI5:=25*:O"HH34G3FM;QFERR5GHV9U8.
MK2JTXSE3=2G."J0TG3<XN*G%W7O1;YHZK5+4_@"_X(F?M'_M;:S_ ,%(OAOH
M.F_$3XC^/-(^)][XJ?XY:+XH\2Z]K^D:EX5LO#FJZAJ/BK7X=5N[FWM-5\.Z
MA;:=-HVKLL%XNH/;>'H)S;ZQ+8W7]97_  4V^ _CWXO_  W\$^)/A]I.I>)M
M1^'&KZW/J?A?1XKB\U74-(\26^EP3:AINE6RR3:K>:5=:1:+]DMH9KT65_>S
MVZ,D5PK>7_\ !77]IO5O^"=W[)VM_&[]GGX>> M%^+_Q0^)V@_#"#QLO@W1G
M.@7?BS2O%OB[5O&NMVUO81)XEU!(?"%U:Z=%X@FN-,;Q+J^F:EJUMK$%K+H^
MI?#O_!"+_@J%^U+^VA\2OC%\&/VEM;L/B+/X4^']K\2?#'Q#LO!GAKP??:<+
M?Q+I/AG5/"^N1>"M)T#PS=IJ8U^QU/02NB6>I1C2-?\ /N]0@>&/3O=\3.$H
M^+/"&<XFM@Z.4Y+6P5'+\0L/B8O,'5PF+HXFCCJ<5AH4)QPN)6&2IU7&4Z5!
MPM*#BEQ>&'&5;PEXSR2OA*\LSSG!8ZICZ$<30DLO=+&82KA*^"JOZPZ\'BL+
M/$)U:2E&G4KQFFIQDY?1'_!-?]FGXP>'?C _Q9\9>%/$G@/PKH7AK6=/MD\3
M:==:#?>);_6XOL45I;Z7J5O#?RZ;9QI+J4]ZT,%N+FWTY89IQ)(@_:GPU\2/
MAWXTO]3TKP=X]\%^+-4T1G36=-\->*=#UV_TAXYC;2+J=GI=]=7%@R7"FW=;
MJ.(K,#$P#@K7SC^WM/XOMOV4?BQ/X+EO8=1CT_1O[3ETUI5OT\,-XCTE/$S0
M/!\Z0?V*UW_:;Y"KH_\ :+,0H)K^?7]D"7X@0_M(_"1_AM'J,VO#QAI/V^#3
MS*(YO"HNXF\6QZJ8Y(5_L4^'AJ!U/SY4B$ +!EF$)'\>_P"LF%\"\TX6\-<I
MRC'Y_A\ZKTLSS#-,16Y,76KYOCGEBAEN$H4)4I5,/'!4Y/#N?[Q.E3YXU:LZ
M[_LU\*XSZ1.3\8^+&<YWEO#6*R"A6RG+,GPU#VF"HX?),NAFSJ9KC<1B(5H4
ML4\=4A'$J'[N2JU>25&C##']9E%?*GQY_;,^!W[.VL67AOQUK&K7_B>\M$U!
MO#GA73$UC4["PF;;;76J&:\L+'3Q= /):V]Q>I>3P(;A+8V[PRR>V?#'XG^"
M?C#X+TCQ]\/]:AUSPYK"/Y,ZH\%U:7<#>7>:;J=E,%N+#4K*7,=S:SHK &.>
M%IK6>WGE_H;"\1Y#C<UQF183.,NQ.<Y?#VF-RRABZ-3&8:"<8R=6A&;G'V<I
MTXU4U>E*I3C44'.*?\PXOA;B3 9-@>(L;D6:83(LSJ>RP&;8C!5Z6 Q<W&<H
MQH8F<%3G[2-.I*DT[5HTZDJ3FJ<W'OZ*X*/XJ_#";Q;+X!A^(O@:7QS _ES>
M#H_%>A/XGBEQN,#Z$M^=36X52KO ;;SDC>.1T5)(V;S3]I7]I'P7^S+X"7QE
MXJ@NM7U#4KS^RO"WA;3Y%AO_ !#JH3SIHA=R130:=I]C;!KK4=3N8WCMXQ'!
M!#=W]W965SIC<]R;+LNQ^;8S,\'1R[*U5>88OV\*E+"RHM*I2J^R=22KJ4HT
MUAU%UYU9PI0IRJ3C%Y9?P[GN:9IEN2X#*<=7S3.)45EF"^KSIU<9&NG*E5H^
MV5.#P[A&566)E*.'A1A.M4JQI0G./T17YZ>+O^"F7[-_A'X@W7@65O&.M6FF
MZB^E:KXVT#2-.O\ PI9W<,S07+02'68=8U2RLY4=;B]TO2;N*95\S31J,;*Q
MT_V7OV[?!'[46N:OX D\*ZQ\/?&":->ZG9V,NMP:Q9ZKIL#I;WC:5K=O9:/=
M1:K91W$5VUM)I<12#S;BVN9OLLI7\:O&_P"P-^TOX:^(E[X)T7X<:[XMTV75
MY+30?&.DQPR>&M2TV64&RU&_U>62&ST,FW=#?PZO)9-:W*3QKYL:1RR_BGB%
MXG<1/(N',\\*,-3XER[,<PQF&S#'8?*\=F$\/6POU;ZM@*N 5.CBL*\8ZM?G
MG6HTZL52I1IRIRKTYS_H#PQ\(^%O]8N*>'O&;%U>$\TRO+,%B\MR_$YOE^64
M\31Q;Q7UK,:.9.I7P>,6!C2P_LZ="O5I2=:M*K&K'#U80_1OXD?\$O\ P#\6
MO&,_Q/\ AU\6)O"WA3Q[>+XOFT5/"\/B&Q-OXA*ZO/=>&-2CUS1OLNGWWVIK
MG3K*ZL;J*RCN42*8VT$5K7Q]_P %.O\ @J'J'_!)BT^"/[)_[-/PV\+>+/&3
M?#:R\<7.M_%I=>U;P[IG@^]\2^(] M;B?3_"6L^#+S6O%GBKQ'X<\5ZGJL]M
MJ^C:7I$BQRP:3-!J$%G9?<O[4?[9OPR_X)+_ +)'P>?XF:=KGQ'\4FST/X=^
M$O"'AF:&PNO%6OZ7I<5]XHU%]7U%)[70_#>B0&67[3-#?71>ZT;3;>QF-U+<
MVGPMX?\ "_[!G_!Q;\/5^(GB#0_B[\&/C!^SY?IX,UV'P_XC\*Q>*]+\/^*_
MM&N:"CWMUH_BCP_XK\"ZW<6.M-H]U?\ A[P_XBTOQ%I7BJT@AM=-D2^U[]U\
M,?#?A;AC$?Z]XO@M9;1SFA&.>UL-6Q&)I4<=74*U7"TJ-3%25+!4\RDH58X*
ME0PU6M3I*49NE"DOP3Q/\3^+^+,/#@2/&U7.J7#^)J?ZO4\50PV%JU\%AG/#
MX?&5ZU+"0G7QU3+5S4Y9A7Q&+HT:M;EG%5:E27WY_P $Q_VF/AA^WY\$M/\
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M=,L?#NN:G=:I(\:Z=%=>8F[\&/$W[,7PR_:S_P"#A3]H7X8_&&'6=4^'FG>
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M5N%TSQ#H\ZV^M>&M6-M)'<_V3K^G:;J/V:6*X-KY,L;M_)5_P31U+]E?P?\
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MM>@^R:A;36_F7&EPQ3[/-MI)H621OY?O^"?7[./[//C3_@LI_P %#?A?XQ^
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MZ?9ZIJ'B27PU8ZIH+.MK?Z#X+\+:'9V=CX=O(YM%UK5];U;6M>L;W4%,D_\
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M75^+:^U;6)_%-_+=W6EZ0]C:Z2MG(MS^#O@__@V__:@\/?M:Z-;3_$/P-/\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R'COX?>
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8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>acrv-20250514.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-13T11:30:14.7818+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://acrivon.com/20250514" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:acrv="http://acrivon.com/20250514" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acrv-20250514.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 14,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Acrivon Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001781174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-5125532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">480 Arsenal Way<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">207-8979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACRV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $2!KEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( $2!KEH1#%&%[@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=XZ[1A"49<+B!-(2$P"<8L<
M;XMHVB@Q:O?VI&7KA. !.,;^\_FSY :#PC[2<^P#17:4KD;?=DEAV(@#<U
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%
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M?^:+X3]>?P%02P$"% ,4    " !$@:Y:1L=-2)4   #-    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $2!KEH1#%&%
M[@   "L"   1              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( $2!KEJ97)PC$ 8  )PG   3              "  > !  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 1(&N6D/* ].'!   T1$
M !@              ("!(0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( $2!KEJ?H!OPL0(  .(,   -              "  =X,  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ 1(&N6I>*NQS     $P(   L
M         ( !N@\  %]R96QS+RYR96QS4$L! A0#%     @ 1(&N6CJJHN=
M 0  / (   \              ( !HQ   'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( $2!KEHD'INBK0   /@!   :              "  1 2  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $2!KEIED'F2&0$
M ,\#   3              "  ?42  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     )  D /@(  #\4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="acrv-20250514.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="acrv-20250514.htm">acrv-20250514.htm</File>
    <File>acrv-20250514.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "acrv-20250514.htm": {
   "nsprefix": "acrv",
   "nsuri": "http://acrivon.com/20250514",
   "dts": {
    "inline": {
     "local": [
      "acrv-20250514.htm"
     ]
    },
    "schema": {
     "local": [
      "acrv-20250514.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_1a02633c-8ea7-4598-be69-c7ba40f352c8",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acrv-20250514.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a02633c-8ea7-4598-be69-c7ba40f352c8",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acrv-20250514.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://acrivon.com/20250514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-071385-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-071385-xbrl.zip
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MF[+19M7JD9_P <KR020^[/4IERS?<OOWASV:WH1QBQ9Y\K>PUT]2P'=^^!_
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M^7N4!"CO"OFI2,&"A%Y.[UF7QC="1HGD9^(9Y@A"P4(%=Y9*ZW'<NI3#D^
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M]%>A[H! I?X#/XMUD4%J2.0\E<I+MN07&?  ]%+TY<5"60,=@PKI#U.EQT$
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M;32PI2'QJ'3YF-KT?[='43FM9'5PG-:YCP'^%BC_A Z2__:U^:;\@#7Y1AB
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M;O/;^BZ_8-?:_)Z$N3!#2[_:<6&1%Z!&NX/Y($Q06OI[8/H;<9&8J\3;]]?
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MQ_T\D4/E0AP-.0!%<"+C*SFU%.1X^7W?1-,?_O+R^U$VCG_X?U!+ 0(4 Q0
M   ( $2!KEHRL!*DNA,  #ZR   1              "  0    !A8W)V+3(P
M,C4P-3$T+FAT;5!+ 0(4 Q0    ( $2!KEI5,.W'N@@  ,5D   1
M      "  >D3  !A8W)V+3(P,C4P-3$T+GAS9%!+ 0(4 Q0    ( $2!KEJF
M<I;L8"$  (HX @ /              "  =(<  !A8W)V+65X.3E?,2YH=&U0
52P4&      ,  P"[    7SX

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>acrv-20250514_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acrv-20250514.xsd" xlink:type="simple"/>
    <context id="C_1a02633c-8ea7-4598-be69-c7ba40f352c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781174</identifier>
        </entity>
        <period>
            <startDate>2025-05-14</startDate>
            <endDate>2025-05-14</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_33d4e64f-3f52-4ba0-bef6-6779b565e7ba">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_23a37b71-388a-4bbc-9ddf-f9fbb14f948e">0001781174</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_8fd061a5-7eb9-44cc-83aa-3e3e3933d768">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_a28e4c0b-3c40-4fdc-8176-cdc2220969dd">2025-05-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_25f5da7f-4a45-4653-bd58-bc95a3b90a34">Acrivon Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_1abd551b-5446-4d76-81d8-1adaf1e1af9a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_53aebc5f-74ec-4d8c-b60b-ce4f208eaaa2">001-41551</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_25c452f7-32d4-416b-8fac-c81296bb7955">82-5125532</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_22ef86de-a4cd-44f3-a98e-377f91b2ec3f">480 Arsenal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_7585b826-1ebe-4bee-8ff7-481e2cb2df08">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_e892e497-5b05-402d-92b9-9a4e4dd7433c">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_16c4511b-e945-4a2f-9e24-efde486800c1">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_001dcf43-9ffa-410e-b828-4388e7d8a959">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_dac99808-dea7-4937-8bb0-849ce2c10bd9">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_26fac416-9d34-42e7-83b3-97977c9cd7a9">207-8979</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_cb36f590-d221-4caf-91cf-cfc71492eeb0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_58e8ed3b-a4e9-4311-968d-059d5e779b4a">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_faf7ccac-f898-4e8a-a0c9-87f5a1175adb">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_e9182866-2e72-4c73-97b4-8490b41214ba">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_151bd1c2-dd8f-4e64-b98e-85ce23891f86">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_817ba231-3023-4eb4-96aa-6d85da26929b">ACRV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_ccf23ca2-0ee6-431b-a483-621c2d860d5f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_c02ad7c9-cafc-478a-8f11-b180d94efa77">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_1a02633c-8ea7-4598-be69-c7ba40f352c8"
      id="F_83b582c6-feb3-46da-8fa1-a295d4688f41">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
